Hook / Thesis
HealthEquity (HQY) is a cash-generative fintech play centered on health savings accounts (HSAs). The last reported fiscal year delivered a classic compounding outcome: accounts rose, HSA assets increased and the portion of assets invested grew substantially. Those three levers - account growth, asset growth and investment penetration - combine into a recurring-fee flywheel that can expand revenue without a commensurate rise in fixed costs. After a volatile 2025 tied to cyber and fraud headlines, the company’s operational metrics have stabilized and the share price has pulled back from its 52-week high, creating an actionable long entry.
Why this matters now
HQY’s core business benefits from secular tailwinds: employer-sponsored health plans, rising healthcare costs, and a policy backdrop that nudges consumers toward tax-advantaged savings. Beyond that, the company is showing evidence that customers are shifting more HSA dollars into investments - a higher-margin revenue stream. With a market capitalization near $7.36 billion and recurring free cash flow, the risk/reward looks favorable from current levels if management sustains growth and keeps execution tight.
Business overview - what investors should care about
HealthEquity operates a technology-enabled platform that administers HSAs and related consumer-directed benefits. The two numbers investors should watch are account counts and HSA assets, since revenue scales with both the number of accounts and dollars on platform (especially invested dollars, which carry higher fees).
Recent operating milestones are tangible: HSAs grew 7% to 10.6 million accounts, while total accounts reached 17.8 million. HSA assets expanded 14% to $36.5 billion and, importantly, HSA investments were up 26% to $18.5 billion. The firm also reported record fourth-quarter new HSA sales, growing 17% year-over-year and adding over one million new HSA accounts during the fiscal year. These are not incremental statistics - higher invested balances materially lift fee revenue per account and create a durable margin profile.
Financial and valuation framing
Valuation is reasonable for a recurring-fee fintech: market cap sits around $7.36 billion. On a per-share basis, trailing earnings per share are approximately $2.57, implying a P/E in the low-to-mid 30s versus the market. Price-to-sales is roughly 5.52 and price-to-book sits near 3.44. The company generates meaningful free cash flow - reported free cash flow is about $408.6 million - which yields roughly 5.5% on the current market cap. Enterprise value metrics show EV/Sales near 6 and EV/EBITDA around 16.4.
Those multiples are not bargain-bin cheap, but the tag is supported by a high-quality recurring revenue base, attractive unit economics for investment balances, and a solid balance sheet (debt-to-equity approximately 0.45). Return on equity is roughly 10.2%, and the company sits with a conservative current ratio near 3.27, giving it liquidity to invest behind product and security.
Technical and market context
Technicals favor the bulls at the moment. The stock is trading above its 10/20/50-day moving averages (10-day SMA $83.82; 50-day SMA $82.54), and momentum indicators show a bullish MACD and an RSI around 62 - supportive but not overbought. Short interest has shown several swings, and the most recent settlement indicates a days-to-cover figure above 5 on 04/30, implying the potential for short-term squeezes during positive news flow. Average volume has compressed from 52-week extremes; recent two-week average volume sits below longer-term levels, signaling the opportunity for a directional move on catalyst-driven flows.
Catalysts to watch
- Upcoming quarterly results and guidance cadence - continued growth in HSA investments would be the primary upside trigger.
- Further acceleration in new HSA sales or large client wins that increase account acquisition velocity or conversion of existing account balances into investments.
- Product adoption tailwinds from new tools (e.g., AI-driven education and tools that simplify benefits), which can lift engagement and investment penetration.
- Any positive commentary on cyber defenses and fraud mitigation that repairs investor sentiment from prior headlines.
Trade plan (actionable)
Thesis: Buy HealthEquity to ride continued compounding of fee-bearing HSA assets and investment penetration, with a disciplined stop in place to limit downside if execution or headline risk reappears.
| Trade | Entry | Stop Loss | Target | Horizon |
|---|---|---|---|---|
| Long | $87.78 | $78.00 | $110.00 | Long term (180 trading days) |
Rationale: Entering at $87.78 captures the current level where both fundamentals and technicals align. The stop at $78.00 protects capital if the shares break meaningful support and it reflects a roughly 11% downside from the entry. The target of $110 is grounded in re-rating toward the prior cycle highs and reflects upside from improved revenue mix and higher FCF conversion; it also sits below the 52-week high of $116.65, making it reachable in a constructive market environment.
Trade timeframe: I expect the trade to play out over a long term (180 trading days) because the compounding effect of increased invested balances and account growth takes multiple quarters to show up meaningfully in reported fee revenue and margin expansion. If you prefer a staged approach, consider taking partial profits around $100 in the mid term (45 trading days) and letting the remainder run toward $110 on accelerating fundamentals.
Risk profile and counterarguments
This is a fundamentally constructive but execution-sensitive idea. Key risks include:
- Security and fraud headline risk - the company has previously cited rising cyber threats and fraud attacks as a driver of earnings pressure and investor concern. Any new incident could quickly re-price the stock.
- Slower HSA acquisition or investment penetration - if new HSA sales cool or customers keep balances in cash rather than moving to investments, revenue growth and margin expansion would decelerate.
- Valuation compression - multiplicative upside assumes multiple expansion or sustained above-trend growth; with a P/E in the low-to-mid 30s, an earnings miss or macro risk could compress valuation rapidly.
- Regulatory or competitive pressure - changes in tax policy affecting HSAs, or more aggressive pricing and product moves from competitors, could pressure growth and fee rates.
- Event-driven liquidity risk - short interest and spikes in short volume have created volatile sessions historically; rapid flows could amplify downside in negative news scenarios.
Counterargument: One could reasonably argue that HQY is no longer a deep-growth story and that the current multiple already prices in steady-state growth plus some optimism about investment penetration. If macro or employment trends cool, account additions and asset inflows may disappoint and leave the stock trading materially lower. That is a credible pathway and the primary reason the trade includes a tight, explicit stop.
What would change my mind
I would downgrade the thesis if management reports sustained declines in new HSA sales (several consecutive quarters of negative year-over-year new-sale growth), a material rollback in HSA investment penetration, or any significant cybersecurity breach that meaningfully increases operating expenses and damages client trust. Conversely, I would become more constructive if the company beats on both new-account additions and HSA investment growth and raises full-year guidance, or if free cash flow conversion improves materially above the current run-rate, which would justify a higher multiple.
Conclusion
HealthEquity combines recurring, transaction-light revenue with a compelling cross-sell opportunity as customers migrate HSA dollars into investments. Recent reported metrics - double-digit growth in invested balances, record new HSA sales, and robust account counts - show the flywheel is still turning. The stock is not cheap, but current valuation is supportable given steady free cash flow and the stickiness of the business. The proposed long at $87.78 with a $78 stop and a $110 target offers a disciplined way to own the compounding story while limiting headline-driven downside.
Key monitoring points
- Quarterly cadence: pay attention to both account growth and the mix shift into investments.
- Security posture and remediation updates in any earnings or investor calls.
- Changes in guidance - upside revisions would validate the thesis; downgrades would tighten the stop or prompt an exit.
- Volume and short-interest dynamics around earnings - these can amplify moves in either direction.
Trade with position sizing that respects the stop. This is a trade that favors disciplined risk control and patient time arbitrage: the compounding benefits of HSA assets and invested balances will be most visible over multiple quarters.